Journal ArticleDOI
Therapeutic Targeting of the Tumor Microenvironment
TLDR
A comprehensive analysis of the current therapies targeting the tumor microenvironment (TME) is provided in this paper, combining a discussion of the underlying basic biology with clinical evaluation of different therapeutic approaches, and highlighting the challenges and future perspectives.Abstract:
Strategies to therapeutically target the tumor microenvironment (TME) have emerged as a promising approach for cancer treatment in recent years due to the critical roles of the TME in regulating tumor progression and modulating response to standard-of-care therapies Here, we summarize the current knowledge regarding the most advanced TME-directed therapies, which have either been clinically approved or are currently being evaluated in trials, including immunotherapies, antiangiogenic drugs, and treatments directed against cancer-associated fibroblasts and the extracellular matrix We also discuss some of the challenges associated with TME therapies, and future perspectives in this evolving field SIGNIFICANCE: This review provides a comprehensive analysis of the current therapies targeting the TME, combining a discussion of the underlying basic biology with clinical evaluation of different therapeutic approaches, and highlighting the challenges and future perspectivesread more
Citations
More filters
Journal ArticleDOI
Clinical relevance of tumour-associated macrophages
TL;DR: The diversity of TAMs suggests different possibilities for exploiting particular subsets for therapeutic purposes; as a result, an arsenal of macrophage-targeted agents are currently being tested in the clinic and the inclusion of TAM data in precision oncology molecular tumour boards could become routine practice.
Journal ArticleDOI
Notch signaling pathway: architecture, disease, and therapeutics
TL;DR: In this article , a review of the history, architecture, regulatory mechanisms, contributions to physiological development, related diseases, and therapeutic applications of the NOTCH pathway is presented. But, the authors emphasize that the outcomes of NOTCH signaling are changeable and highly dependent on context.
Journal ArticleDOI
Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion.
Xiujie Sun,Bogang Wu,Huai-Chin Chiang,Hui Deng,Xiaowen Zhang,Wei Xiong,Junquan Liu,Aaron M. Rozeboom,Brent T. Harris,Eline Blommaert,Antonio Gomez,Roderic Espin Garcia,Yufan Zhou,Payal Mitra,Madeleine Prevost,Deyi Zhang,Debarati Banik,Claudine Isaacs,Deborah L. Berry,Catherine Lai,Krysta Chaldekas,Patricia S. Latham,Christine A. Brantner,Anastas Popratiloff,Victor X. Jin,Ningyan Zhang,Yanfen Hu,Miguel Angel Pujana,Tyler J. Curiel,Zhiqiang An,Rong Li +30 more
TL;DR: In this article, the extracellular domain of the discoidin domain receptor (DDR1) was found to be necessary and sufficient for immune exclusion in triple-negative breast cancer.
Journal ArticleDOI
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
TL;DR: Both oncogene and non-oncogene addiction stand out as promising targets to robustly inflame the TME and potentially enable superior responses to ICIs.
Journal ArticleDOI
Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics
Uttpal Anand,Abhijit Dey,Arvind K. Singh Chandel,Rupa Sanyal,Amarnath Mishra,Devendra Kumar Pandey,Valentina De Falco,Arun Upadhyay,Ramesh Kandimalla,Anupama Chaudhary,Jaspreet Kaur Dhanjal,Saikat Dewanjee,Jayalakshmi Vallamkondu,José M. Pérez de la Lastra +13 more
TL;DR: In this paper , the authors reviewed the existing and contemporary advancements in chemotherapy and assessed the status of the enrolled drugs/pharmaceuticals; they also comprehensively discussed the emerging role of specific/targeted therapeutic strategies that are presently being employed to achieve better clinical success/survival rate in cancer patients.
References
More filters
Journal ArticleDOI
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more
TL;DR: Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma.
Journal ArticleDOI
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
Herbert Hurwitz,Louis Fehrenbacher,William Novotny,Thomas Cartwright,John D. Hainsworth,W. Heim,Jordan Berlin,Ari David Baron,Susan Griffing,Eric Holmgren,Napoleone Ferrara,Gwen Fyfe,Beth Rogers,Robert W. Ross,Fairooz F. Kabbinavar +14 more
TL;DR: The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer.
Journal ArticleDOI
Microenvironmental regulation of tumor progression and metastasis.
TL;DR: The paradoxical roles of the tumor microenvironment during specific stages of cancer progression and metastasis are discussed, as well as recent therapeutic attempts to re-educate stromal cells within the TME to have anti-tumorigenic effects.
Journal ArticleDOI
Pembrolizumab for the treatment of non-small cell lung cancer
Edward B. Garon,Naiyer A. Rizvi,Rina Hui,Natasha B. Leighl,Ani Sarkis Balmanoukian,Joseph Paul Eder,Amita Patnaik,Charu Aggarwal,Matthew A. Gubens,Leora Horn,Enric Carcereny,Myung-Ju Ahn,Enriqueta Felip,Jong-Seok Lee,Matthew D. Hellmann,Omid Hamid,Jonathan W. Goldman,Jean-Charles Soria,Marisa Dolled-Filhart,Ruth Z. Rutledge,Jin Zhang,Jared Lunceford,Reshma A. Rangwala,Gregory M. Lubiniecki,Charlotte Roach,Kenneth Emancipator,Leena Gandhi +26 more
TL;DR: Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer and PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolIZumab.
Journal ArticleDOI
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert,Caroline Robert,Caroline Robert,Jacob Schachter,Georgina V. Long,Ana Arance,Jean-Jacques Grob,Laurent Mortier,Laurent Mortier,Adil Daud,Matteo S. Carlino,Catriona M. McNeil,Michal Lotem,James Larkin,Paul Lorigan,Bart Neyns,Christian U. Blank,Omid Hamid,Christine Mateus,Christine Mateus,Ronnie Shapira-Frommer,Ronnie Shapira-Frommer,Michele Kosh,Honghong Zhou,Nageatte Ibrahim,Scot Ebbinghaus,Antoni Ribas +26 more
TL;DR: The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma.
Related Papers (5)
Microenvironmental regulation of tumor progression and metastasis.
A framework for advancing our understanding of cancer-associated fibroblasts
Erik Sahai,Igor Astsaturov,Edna Cukierman,David G. DeNardo,Mikala Egeblad,Ronald M. Evans,Ronald M. Evans,Douglas T. Fearon,Douglas T. Fearon,Florian R. Greten,Sunil R. Hingorani,Tony Hunter,Richard O. Hynes,Rakesh K. Jain,Tobias Janowitz,Claus Jørgensen,Alec C. Kimmelman,Mikhail G. Kolonin,Robert G. Maki,Robert G. Maki,R. Scott Powers,Ellen Puré,Daniel C. Ramirez,Ruth Scherz-Shouval,Mara H. Sherman,Sheila A. Stewart,Thea D. Tlsty,David A. Tuveson,Fiona M. Watt,Valerie M. Weaver,Ashani T. Weeraratna,Zena Werb +31 more